

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (for Ohio Only)

Policy Number: CSOH2024D0108.B
Effective Date: August 1, 2024

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	1
Policy History/Revision Information	2
Instructions for Use	2

Related Policies
None

Application

This Medical Benefit Drug Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Coverage Rationale

Leqembi® (lecanemab-irmb) is proven and medically necessary for the treatment of certain conditions outlined within the InterQual® criteria. For medical necessity clinical coverage criteria for Leqembi®, refer to the current release of the InterQual® guideline for Leqembi: CP: Specialty Rx Non-Oncology, Lecanemab-Irmb (Leqembi®).

[Click here to view the InterQual® criteria.](#)

Aduhelm® (aducanumab-avwa) is proven and medically necessary for the treatment of certain conditions outlined within the InterQual® criteria. For medical necessity clinical coverage criteria for Aduhelm®, refer to the current release of the InterQual® guideline for Aduhelm: CP: Specialty Rx Non-Oncology, Aducanumab-Avwa (Aduhelm®).

[Click here to view the InterQual® criteria.](#)

The Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease (AD) when furnished under coverage with evidence development (CED). Approved CED studies are posted on the CMS Coverage with Evidence Development webpage (refer to the CMS [Coverage with Evidence Development](#)).

On January 31, 2024, Biogen announced as a company they will discontinue the development and commercialization of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J0172	Injection, aducanumab-avwa, 2 mg
J0174	Injection, lecanemab-irmb, 1 mg

Policy History/Revision Information

Date	Summary of Changes
08/01/2024	<p>Coverage Rationale</p> <p>Leqembi® (lecanemab-irmb)</p> <ul style="list-style-type: none"> Revised language to indicate Leqembi® (lecanemab-irmb) is proven and medically necessary for the treatment of certain conditions outlined within the InterQual® criteria; for medical necessity clinical coverage criteria for Leqembi®, refer to the current release of the InterQual® CP: Specialty Rx Non-Oncology, Lecanemab-Irmb (Leqembi®) <p>Aduhelm® (aducanumab-avwa)</p> <ul style="list-style-type: none"> Added notation to indicate on Jan. 31, 2024, Biogen announced as a company, they will discontinue the development and commercialization of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study <p>Applicable Codes</p> <ul style="list-style-type: none"> Removed list of applicable ICD-10 diagnosis codes: G30.0, G30.1, G30.8, and G30.9 <p>Supporting Information</p> <ul style="list-style-type: none"> Removed <i>Background</i>, <i>Clinical Evidence</i>, <i>FDA</i>, and <i>References</i> sections Archived previous policy version CSOH2024D0108.A

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]), or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC), or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC), or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state (OAC), or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.